https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twMain Products/ Services/ Pipelines & Platforms
▪ Pdia4 expressed specifically in β cells, and increases in response to excess nutrient. Pdia4 positively regulated β cell death, dysfunction, and ROS production. ▪ Using molecular docking and modification, PS-001 was identified as a Pdia4 specific inhibitor. ▪ PS-001 can prevent β cell dysfunction and death via reduction of ROS induced by nutrient. Furthermore, PS-001 alone or combined with other diabetes drug can stabilize blood glucose and reverse diabetes in mice. ▪ PS-001 is a first-in-class drug which can treat and reverse diabetes through a novel mechanism. ▪ The US IND of PS-001 had been approved in 2022Q1, and the Phase I clinical trial will be launched in 2022Q2. ▪ The Phase II trial will be completed in 2025, and will be licensed out to global pharmaceutics. ▪ The PS-002 (same API of PS-001) is potential to treat Type I diabetes.
Business Interests
We are looking for collaboration with and out-licensing to global pharmaceutics
Contact Info
Tzung-Yan Chen
COO
+886-2-2653-8670#2044; +886-937-457-634
zong770115@gmail.com